A panel of Alzheimer’s disease (AD) experts has developed a plan to break down barriers to trial enrollment and accelerate research to keep up with the expected increase in the disease’s prevalence in the coming decades. Read More
Sponsors are increasingly using questionnaires to gather data and feedback from trial participants on their experience with the investigational product and the trial in general as part of a push to enhance engagement. And while participants usually appreciate the opportunity to contribute, too-frequent surveys can wear on their patience and create additional work for site staff. The question that must be considered is “how do you create a balance between benefit and burden for both participants and staff?” Read More
A broad collaboration among regulators, academia, the nonprofit sector and sponsors has developed a framework for creating less restrictive eligibility criteria for lung cancer trials that can be applied across the oncology research sector and beyond. Read More
There’s considerable buzz around the idea of letting trial participants use their own electronic devices to run trial apps, and the strategy has risen in popularity alongside the decentralized trials (DCT) movement. For sites unfamiliar with BYOD (bring your own device) trials, planning and prepping with the technology in mind is essential to managing this still evolving model successfully. Read More
The clinical trial payment process has long been frustrating for sites as well as sponsors and their CROs, with uncertain invoicing procedures, misunderstandings around payment terms and data entry complications often leading to late, incorrect or missed payments. Add to the picture the trend toward increased trial complexity, adoption of new technologies and the use of decentralized trial (DCT) methods, and all parties are feeling the pinch of payment problems more than ever. Read More
Sponsors, sites and academic institutions generally agree that the clinical trials industry needs formalized education programs and requirements for trial professionals, especially in light of a new survey that shows large competency gaps in several core areas.
Sponsors take an average of six years to adopt innovations intended to increase trial efficiency, according to findings from a new global survey. Now, an industry that moved at unprecedented speed to adapt to the COVID-19 pandemic is looking to leverage that experience and identify ways to shorten the six-year innovation cycle. Read More
While the pandemic’s impact on clinical trials has been evident — trials paused or closed, new trial starts delayed, enrollment and retention declining — some hard data from two renowned research institutions have cast light on the pandemic experience. Read More
There’s been considerable skepticism about using decentralized trial (DCT) approaches in cancer trials, with procedural complexity, nature of disease and other considerations lending themselves more to in-person visits. But a new survey shows cancer patients have greater interest in trials when remote technology cuts down on travel and other participation burdens. Read More
The FDA may have stressed the importance of sponsors having effective, feasible diversity plans for each trial in its recent guidance, but true diversity can’t be achieved without site involvement, experts agree. Read More